Research programme: dual aurora/FLT kinase inhibitors - Sareum
Latest Information Update: 29 Jul 2016
At a glance
- Originator Sareum
- Class Small molecules
- Mechanism of Action Aurora kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Vascular endothelial growth factor receptor 3 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Cancer